TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2019-12-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/47430 |